Interview, Fireside Chat
The Future Of Brain-Computer Interfaces
- Max Hodak, co-founder of Neuralink and founder of Science, asserts it is highly probable that the first individuals to live to 1,000 years are currently alive, driven by an imminent "takeoff era" in biotechnology rather than incremental advances.
- Science recently announced that over 40 people have received the "Prima" retinal implant, a 2mm x 2mm silicon chip with an array of solar panels that bypasses dead rods and cones to restore vision in patients with macular degeneration.
- The Prima system utilizes a two-step process: external glasses capture visual data via a camera, and a laser projector transmits this information to the implanted chip, which excites retinal cells to stimulate the optic nerve, effectively creating form vision rather than just phosphenes (flashes).
- Clinical trials for the Prima implant were conducted across 17 sites in Europe and published in the New England Journal of Medicine last fall, with the company now submitting for market approval, targeting a decision later this year.
- The global addressable market for the Prima device includes approximately 200 million people affected by age-related macular degeneration, with the severe "geographic atrophy" form affecting 1–2 million people specifically.
- Science distinguishes three distinct branches of its pipeline: retinal prosthetics (Prima), bio-hybrid neural interfaces, and perfusion systems (Vessel).
- Bio-hybrid neural interfaces involve implanting devices seeded with hypoimmunogenic, stem cell-derived neurons that grow into the host brain, forming biological connections akin to a "new cranial nerve" or the "Avatar" Q-tip, avoiding the need for genetic modification of the patient's own cells.
- Neuroplasticity research indicates that while critical periods in early development are essential for certain visual functions, the adult brain retains significant plasticity when provided with feedback, allowing users to learn to control neural signals within minutes.
- Hodak notes a historical precedent of critical periods: patients who were born blind due to congenital cataracts and received vision restoration as adults often failed to perceive coherent images, resulting in severe psychological distress, whereas restoring sight in those who previously had vision is more successful.
- The company's "Vessel" program aims to revolutionize organ preservation by creating portable, backpack-sized perfusion devices (ECMO alternatives) to extend the viability of donor organs, addressing the economic and ethical failures of current "bridge to nowhere" therapies.
- Current BCI applications for healthy users (e.g., motor decoding at 10 bits/second) are currently inferior to standard interfaces like keyboards (40 bits/second), meaning widespread adoption by healthy individuals will likely await higher bandwidth, bidirectional interfaces.
- Hodak predicts that within 10 years, BCIs could achieve near-native acuity with color vision, and over the next 20 years, the technology will enable high-bandwidth connections that reframe healthcare from drug discovery to direct neural engineering.
- The industry is shifting from viewing BCI as a single product to a category with multiple modalities, including ultrasound-based non-invasive stimulation for focus/sleep and fully implantable electrical probes for severe disability.
- Hodak draws a parallel between current BCI progress and the early PC revolution, suggesting that while current devices are low-bandwidth, they represent the foundational step toward "conscious machines" and eventual human-AI merging.
- The "Prima" implant is agnostic to the underlying cause of blindness (e.g., macular degeneration, retinitis pigmentosa, Stargardt's disease), offering a solution that treats the symptom (loss of photoreceptor function) rather than the specific genetic mutation.
- Hodak contrasts the inefficiency of drug discovery (taking decades with high failure rates) with the engineering precision of neural interfaces, citing the Prima trial's ability to restore letter-reading capabilities to patients who had been blind for a decade.
- Insights from AI research have unified with neuroscience, revealing that brain representations (latent spaces) and AI model representations function similarly, validating the approach of treating the brain as a computer with defined input/output APIs.
- Hodak attributes the miniaturization of BCI electronics to the "smartphone dividend," where massive investments by tech giants in low-power, high-density chips enabled fully implantable devices that can be closed against the skin to prevent infection.
- Future directions include exploring non-surgical ultrasound for consumer applications (e.g., digital sleeping pills) and utilizing bio-hybrid interfaces for conditions like glaucoma where the optic nerve is severed, which electrical implants currently cannot treat.
- The company views consciousness as a measurable physical phenomenon that can be studied via ultra-high bandwidth BCIs, potentially leading to the discovery of new fundamental physics governing mental processes.
- Hodak reflects that his transition from pure software (founding Transcriptic) to hard tech biotech required acquiring "oral tradition" knowledge of executing complex ventures, a lesson accelerated by his time at Neuralink.
- He expresses optimism about the next 10–20 years, predicting that intelligence will become widely accessible and that BCIs will fundamentally reconfigure the relationship between humans, machines, and each other.
- Specific technical constraints remain, such as the 100x compression of visual signals in the retina, which previous attempts (e.g., Second Sight) failed to overcome by stimulating retinal ganglion cells rather than the upstream bipolar cells where image processing begins.
- The "bio-hybrid" approach is distinct from optogenetics in that it relies on biological neuron growth rather than viral gene therapy to alter the patient's genome, reducing safety risks while maintaining high-bandwidth connectivity.
- Hodak notes that the conjoined twins in Canada with a shared thalamus provide a natural case study for understanding multi-stream consciousness and "phenomenal binding," offering clues for future brain-to-brain communication interfaces.
- The "Vessel" initiative was sparked by ethical dilemmas surrounding ECMO usage for "bridge to nowhere" patients, aiming to create affordable, home-compatible perfusion systems to prevent waste and improve quality of life.
- Hodak advises young founders to seek "high agency" roles in established complex environments (like Neuralink) to learn the nuances of running difficult ventures before founding their own companies.
- The company's IP strategy includes a deep focus on hypoimmunogenic stem cells, allowing for the mass production of neuron grafts without patient-specific manufacturing, a critical step for scalability.
- Hodak posits that the current era of incremental biotech is ending, replaced by a period of rapid exponential growth comparable to the 15 years following the start of the Industrial Revolution.